4month20On the same day, co-hosted by Yantai Caijin Group and Yida Capital, “Discussing Industrial Opportunities Join us on the journey to the 'City of Trillions'2023The Capital Empowering Yantai's Industrial Economy for High-Quality Development Conference and Shandong Yida Fund Investors' Annual Meeting kicked off in Yantai. Leaders from the Yantai Municipal Government and relevant departments directly under it, experts in the domestic capital market field, well-known investment institutions from Shandong and Jiangsu, and40Several leading biopharmaceutical companies200More than a hundred people attended the meeting, which was chaired by Li Hui, General Manager of Yantai Finance and Capital Group.
The conference focused on the industrial characteristics of Yantai, highlighted the new opportunities brought about by Yantai's decisive entry into the 'Trillion Club', shared insights from industry research, deepened exchanges and cooperation, empowered industrial transformation and upgrading with capital, shared the results of regional investment cooperation, and promoted a new chapter in multi-dimensional, in-depth, and precise exchanges and cooperation between Jiangsu and Shandong.
4month21On [date], in order to further explore new opportunities for the 'going global' of the big health industry and promote interactive exchanges within the ecosystem between Yida Capital and Yantai Caijin Group, both parties jointly held the Caijin 'Sishanghui' event and Yida HomeCEOClub Industry Seminar, chaired by Xue Yi, Senior Partner at Yida Capital .
Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the conference. He delivered a speech on "Analysis of the Current Situation and Future Prospects of Chinese Medical Enterprises Going Global" and participated in two special seminars on medical device and biopharmaceutical exports. He engaged in in-depth exchanges with entrepreneurs present, sparked ideas, and jointly sought development.
The biopharmaceutical industry is closely related to life and health, always occupying an important position in national economic development. It is a strategic high-tech emerging industry that is the most active in innovation and develops at the fastest pace during the new round of scientific and technological revolution and industrial transformation. It is also one of the important 'variables' and 'increases' for enhancing regional industrial capabilities. However, in recent years, while the industry has been booming, it has also faced increasingly fierce competition. How to implement the 'going global' strategy to smooth both domestic and international markets, break through development ceilings, and enhance core competitive advantages has become an essential question for many pharmaceutical companies' strategic planning.
Currently, China's biopharmaceutical industry is entering a comprehensive era of 'going global'. Product competitiveness, clinical development capabilities, overseas registration and filing abilities, commercialization capabilities, and global industrial chain capabilities all determine how far Chinese biopharmaceutical enterprises can go abroad.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
During the keynote speech session, Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, delivered a presentation titled "Analysis of the Current Situation and Future Prospects for Chinese Medical Enterprises Going Global," focusing on two areas: biomedicine and medical devices.
In the field of biomedicine, Mao Hua pointed out that in recent years, The research and development of innovative drugs in China is accelerating.license-out operationBecoming an important means for biopharmaceutical companies to go global, multiple factors at home and abroad are also driving Chinese biopharmaceutical companies to 'go global by leveraging other companies' license-out operationRelying on overseas enterprises' R&D experience and commercial capabilities can reduce risks and become a cost-effective and efficient approach.
The data shows,2022China's pharmaceuticals overseas inlicense-out operationRemarkably, despite the unstable external environment, the volume of transactions continued to rise.2022Overseas throughout the yearlicense-outquantity66an2021year55one,2020year74(1);2023Year-end4Monthly transaction volume reaches16one.
atlicense-outIn terms of model, Chinese pharmaceutical companies currently face unclear customized overseas expansion strategies that suit their own capabilities and current situation, insufficient capabilities in overseas clinical trials and registration affairs, and a lack of systematic external communication.BDThree major challenges lie in cooperation experience and talent shortage. Mao Hua said that differentiated products, solid clinical performance, high-quality overseas commercialization resources and registration capabilities, the ability to communicate with regulatory authorities, a suitable commercialization model for oneself, and an international talent reserve are the 'magic weapons' for enterprises to succeed in overseas development.
In the field of medical devices, compared to the domestic market, the overseas market has a larger space. Developed countries have relatively stable pricing and are not affected by centralized procurement policies. The development of Chinese medical devices going global has been in full swing.
"and the innovative drug industrylicense outWhat's different is that currently, the overseas expansion of medical devices mainly relies on direct product sales. ' ' Mao Hua further added, At this stage, leading Chinese medical device companies are leveragingOEM/ODMCommercial licensing, self-declared sales, mergers and acquisitions, and other models have achieved initial accumulation in overseas expansion, and efforts continue to be made in deepening overseas operations (building brand internationalization).
Mao Hua pointed out that unfamiliarity with overseas regulations, lack of understanding of the overseas business environment (difficulty in finding suitable business partners), inadequate localization execution, and low brand recognition are the main obstacles to medical device exports overseas. He stated that enterprises need to conduct thorough research on the market capacity and relevant data of overseas regions, choose the outbound model and region based on their own circumstances, and implement localization execution strategies; do a good job in product positioning analysis and market analysis, make strategic layouts for the entire product lifecycle, adhere to long-termism and a global perspective, and build a systematic and international business system.
After the meeting, Mao Hua participated in two special seminars on medical device and biopharmaceutical exports. Together with the entrepreneurs attending the conference, they had an in-depth exchange on the export experiences, current situation of biopharmaceutical and medical device companies, as well as the direction, models, strategies, and regulations for companies going global. They jointly reflected on practical difficulties and explored ways to break through them.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.
